{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:06:08Z","timestamp":1778583968566,"version":"3.51.4"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"indian council of medical research","doi-asserted-by":"publisher","award":["VIR\/24\/2020\/ECD-I"],"award-info":[{"award-number":["VIR\/24\/2020\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"sir ganga ram hospital (sgrh) delhi, india"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Meningioma is the second most common type of intracranial brain tumor. Immunohistochemical techniques have shown prodigious results in the role of epidermal growth factor receptor variant III (EGFR vIII) in glioma and other cancers. However, the role of EGFR vIII in meningioma is still in question. This study attempt the confer searches for the position attained by EGFR vIII in progression and expression of meningioma. Immunohistochemistry technique showed that EGFR vIII is highly expressed in benign tumors as compared to the atypical meningioma with a highly significant p-value (p&lt;0.05). Further analysis by flow cytometry results supported these findings thus presented high intensity of EGFR vIII in low grades of meningioma. The study revealed that the significant Ki 67 values, to predictor marker for survival and prognosis of the patients. Higher expression of EGFR vIII in low grades meningiomas as compared to high-grade tumors indicate towards its oncogenic properties. To our knowledge, limited studies reported in literature expressing the EGFR vIII in meningioma tumors. Hence, Opinions regarding the role that EGFR vIII in tumorigenesis and tumor progression are clearly conflicting and, therefore, it is crucial not only to find out its mechanism of action, but also to definitely identify its role in meningioma.<\/jats:p>","DOI":"10.1371\/journal.pone.0255133","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T19:09:56Z","timestamp":1632856196000},"page":"e0255133","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploring the role of epidermal growth factor receptor variant III in meningeal tumors"],"prefix":"10.1371","volume":"16","author":[{"given":"Rashmi","family":"Rana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishnavi","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirti","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satnam Singh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir Kumar","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunila","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal Kumar","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-1993","authenticated-orcid":true,"given":"Dharmendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"issue":"3","key":"pone.0255133.ref001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","article-title":"The WHO classification of tumors of the nervous system","volume":"61","author":"P Kleihues","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5 Pt 1","key":"pone.0255133.ref002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3171\/jns.1989.71.5.0665","article-title":"Incidence and clinicopathological features of meningioma","volume":"71","author":"M Rohringer","year":"1989","journal-title":"J Neurosurg"},{"issue":"6","key":"pone.0255133.ref003","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1227\/01.NEU.0000188281.91351.B9","article-title":"Epidemiology of intracranial meningioma","volume":"57","author":"EB Claus","year":"2005","journal-title":"Neurosurgery"},{"issue":"2","key":"pone.0255133.ref004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2008.01.010","article-title":"Meningioma","volume":"67","author":"C Marosi","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"pone.0255133.ref005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"PY Wen","year":"2010","journal-title":"J Neurooncol"},{"issue":"1","key":"pone.0255133.ref006","first-page":"83","article-title":"Current management of meningiomas","volume":"9","author":"F De Monte","year":"1995","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"pone.0255133.ref007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","article-title":"Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas","volume":"108","author":"U Andersson","year":"2004","journal-title":"Acta Neuropathol"},{"issue":"3","key":"pone.0255133.ref008","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"DS Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"pone.0255133.ref009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"R Roskoski","year":"2014","journal-title":"Pharmacol Res"},{"issue":"3","key":"pone.0255133.ref010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.10224","article-title":"Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis","volume":"98","author":"H Ge","year":"2002","journal-title":"Int J Cancer"},{"issue":"7","key":"pone.0255133.ref011","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnen\/63.7.700","article-title":"Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance","volume":"63","author":"KD Aldape","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"pone.0255133.ref012","doi-asserted-by":"crossref","first-page":"e3140","DOI":"10.7717\/peerj.3140","article-title":"Expression and clinical value of EGFR in human meningiomas","volume":"5","author":"MB Arnli","year":"2017","journal-title":"PeerJ"},{"issue":"Suppl 2","key":"pone.0255133.ref013","first-page":"S42","article-title":"First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer","volume":"6","author":"JJ Lee","year":"2007","journal-title":"Clin Colorectal Cancer"},{"issue":"15","key":"pone.0255133.ref014","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1517\/14656566.8.15.2579","article-title":"Erlotinib in non-small-cell lung cancer","volume":"8","author":"C Gridelli","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"pone.0255133.ref015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:BREA.0000041585.26734.f9","article-title":"EGFR and EGFRvIII expression in primary breast cancer and cell lines","volume":"87","author":"JM Rae","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0255133.ref016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6750-10-72","article-title":"Development of an EGFRvIII specific recombinant antibody","volume":"10","author":"P Gupta","year":"2010","journal-title":"BMC Biotechnol"},{"issue":"17","key":"pone.0255133.ref017","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1158\/0008-5472.CAN-15-0989","article-title":"Ligand-Independent EGFR Signaling","volume":"75","author":"G Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"15","key":"pone.0255133.ref018","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.ejca.2006.03.033","article-title":"Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients","volume":"42","author":"HA Silva","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0255133.ref019","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3892\/ijo.2011.1287","article-title":"Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain","volume":"40","author":"A Guillaudeau","year":"2012","journal-title":"Int J Oncol"},{"issue":"4","key":"pone.0255133.ref020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1750-3639.2009.00318.x","article-title":"EGFRvIII-targeted vaccination therapy of malignant glioma","volume":"19","author":"BD Choi","year":"2009","journal-title":"Brain Pathol"},{"issue":"3","key":"pone.0255133.ref021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-009-9889-1","article-title":"Genetically engineered T cells to target EGFRvIII expressing glioblastoma","volume":"94","author":"SS Bullain","year":"2009","journal-title":"J Neurooncol"},{"key":"pone.0255133.ref022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-4598-12-31","article-title":"Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma","volume":"12","author":"Y Katanasaka","year":"2013","journal-title":"Mol Cancer"},{"issue":"16","key":"pone.0255133.ref023","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/jnci\/93.16.1246","article-title":"PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme","volume":"93","author":"JS Smith","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"pone.0255133.ref024","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","article-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas","volume":"89","author":"AJ Wong","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0255133.ref025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-3-38","article-title":"The natural history of EGFR and EGFRvIII in glioblastoma patients","volume":"3","author":"AB Heimberger","year":"2005","journal-title":"J Transl Med"},{"issue":"12","key":"pone.0255133.ref026","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in glioblastoma: prognostic significance revisited","volume":"13","author":"N Montano","year":"2011","journal-title":"Neoplasia"},{"issue":"5","key":"pone.0255133.ref027","doi-asserted-by":"crossref","first-page":"e37204","DOI":"10.1371\/journal.pone.0037204","article-title":"EGFR soluble isoforms and their transcripts are expressed in meningiomas","volume":"7","author":"A Guillaudeau","year":"2012","journal-title":"PLoS One"},{"issue":"22","key":"pone.0255133.ref028","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors","volume":"23","author":"J Felsberg","journal-title":"Clin Cancer Res"},{"issue":"12","key":"pone.0255133.ref029","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"Z An","year":"2018","journal-title":"Oncogene"},{"issue":"12","key":"pone.0255133.ref030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in glioblastoma: prognostic significance revisited","volume":"13","author":"N Montano","year":"2011","journal-title":"Neoplasia"},{"issue":"19","key":"pone.0255133.ref031","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2013.198","article-title":"EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180","volume":"33","author":"H Feng","year":"2014","journal-title":"Oncogene"},{"issue":"Suppl 8","key":"pone.0255133.ref032","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/neuonc\/nou294","article-title":"Molecular pathologic diagnosis of epidermal growth factor receptor","volume":"16 Suppl 8","author":"CL Maire","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"pone.0255133.ref033","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.1219817110","article-title":"Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma","volume":"110","author":"BD Choi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"pone.0255133.ref034","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1440-1789.2007.00750.x","article-title":"Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma","volume":"27","author":"J Bruna","year":"2007","journal-title":"Neuropathology"},{"issue":"1","key":"pone.0255133.ref035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset","volume":"14","author":"BC Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"pone.0255133.ref036","article-title":"CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","author":"T Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0255133.ref037","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1\u20132 study","volume":"20","author":"MJ Ahn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0255133.ref038","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12272-020-01232-3","article-title":"Small molecule tyrosine kinase inhibitors in glioblastoma","volume":"43","author":"G Kim","year":"2020","journal-title":"Arch Pharm Res"},{"issue":"10","key":"pone.0255133.ref039","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"S Park","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"pone.0255133.ref040","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"YH Park","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0255133.ref041","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/cancers12113120","article-title":"rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects","volume":"12","author":"JM Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0255133.ref042","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12882-020-01932-4","article-title":"Discrepant glomerular filtration rate trends from creatinine and cystatin C in patients with chronic kidney disease: results from the KNOW-CKD cohort","volume":"21","author":"E Kang","year":"2020","journal-title":"BMC Nephrol"},{"issue":"7","key":"pone.0255133.ref043","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/1759-7714.13128","article-title":"The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas","volume":"10","author":"H Kim","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"pone.0255133.ref044","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","article-title":"A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients","volume":"15","author":"G Scagliotti","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"pone.0255133.ref045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00018-020-03490-2","article-title":"Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity","volume":"78","author":"DG Kim","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"pone.0255133.ref046","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/carcin\/bgy121","article-title":"SMAD7 in keratinocytes promotes skin carcinogenesis by activating ATM-dependent DNA repair and an EGFR-mediated cell proliferation pathway","volume":"40","author":"HT Ha Thi","year":"2019","journal-title":"Carcinogenesis"},{"issue":"2","key":"pone.0255133.ref047","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2014.11.013","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea","volume":"87","author":"JH Baek","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"pone.0255133.ref048","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-019-0614-0","article-title":"Improved efficacy against malignant brain tumors with EGFRwt\/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations","volume":"7","author":"V Chandramohan","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"pone.0255133.ref049","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4132\/jptm.2020.05.21","article-title":"Intraoperative frozen cytology of intraosseous cystic meningioma in the sphenoid bone","volume":"54","author":"NR Kim","year":"2020","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"pone.0255133.ref050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.14791\/btrt.2015.3.2.147","article-title":"Crush Cytology of Secretory Meningioma: A Case Report","volume":"3","author":"NR Kim","year":"2015","journal-title":"Brain Tumor Res Treat"},{"issue":"2","key":"pone.0255133.ref051","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/SCS.0000000000000535","article-title":"Iatrogenic cerebrospinal fluid oculorrhea","volume":"25","author":"M Chi","year":"2014","journal-title":"J Craniofac Surg"},{"issue":"1","key":"pone.0255133.ref052","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4132\/KoreanJPathol.2014.48.1.77","article-title":"Crush cytology of microcystic meningioma with extensive sclerosis","volume":"48","author":"JY Seok","year":"2014","journal-title":"Korean J Pathol"},{"issue":"2","key":"pone.0255133.ref053","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4132\/jptm.2020.02.04","article-title":"Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea","volume":"54","author":"YJ Cha","year":"2020","journal-title":"J Pathol Transl Med"},{"issue":"4","key":"pone.0255133.ref054","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3340\/jkns.2016.59.4.405","article-title":"Experience with 7.0 T MRI in Patients with Supratentorial Meningiomas","volume":"59","author":"SW Song","year":"2016","journal-title":"J Korean Neurosurg Soc"},{"issue":"5","key":"pone.0255133.ref055","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1159\/000353804","article-title":"Crush cytology of a primary intraspinal rhabdoid papillary meningioma: a case report","volume":"57","author":"J Jeong","year":"2013","journal-title":"Acta Cytol"},{"issue":"3","key":"pone.0255133.ref056","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-009-9879-3","article-title":"Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis","volume":"94","author":"NR Kim","year":"2009","journal-title":"J Neurooncol"},{"issue":"6","key":"pone.0255133.ref057","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.18632\/oncotarget.6874","article-title":"Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)","volume":"7","author":"JY Lee","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"pone.0255133.ref058","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10637-014-0146-x","article-title":"Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors","volume":"32","author":"HS Woo","year":"2014","journal-title":"Invest New Drugs"},{"issue":"2","key":"pone.0255133.ref059","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4143\/crt.2018.324","article-title":"A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13","volume":"51","author":"KH Yoo","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"24","key":"pone.0255133.ref060","doi-asserted-by":"crossref","first-page":"36311","DOI":"10.18632\/oncotarget.8904","article-title":"Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)","volume":"7","author":"SM Lim","year":"2016","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0323060","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T19:11:28Z","timestamp":1632856288000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255133"}},"subtitle":[],"editor":[{"given":"Timir","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255133","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}